{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:38:41Z","timestamp":1794620321714,"version":"4.9.1"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Azacitidine (AZA) plus venetoclax (VEN) has emerged as a widely accepted treatment option for acute myeloid leukemia (AML), particularly in older patients or those unfit for intensive chemotherapy. However, real-world data on AZA\u2009+\u2009VEN efficacy and safety in Southeast Asia remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of AZA\u2009+\u2009VEN in newly diagnosed (ND) and relapsed\/refractory (R\/R) AML patients in Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective observational multicenter study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This is a multicenter retrospective study included ND and R\/R AML patients treated between 2021 and 2024 at three tertiary hospitals in Thailand. All patients received AZA at 75\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for 7\u2009days per cycle. VEN dosing and duration were individualized based on physician judgment, drug availability, and patient affordability. Data collection included clinical characteristics, cytogenetics, treatment details, response rates, survival outcomes, and toxicities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 81 patients were analyzed, included 54 ND and 27 R\/R AML cases, with a median age of 65\u2009years. Based on European LeukemiaNet 2022 classification, 51.9% had intermediate risk, and 33.3% had adverse risk. The composite complete remission was 56.8% (ND: 64.8%, R\/R: 40.7%). VEN was administered at a median dose of 100\u2009mg for 28\u2009days, combined with potent CYP3A4 inhibitor of antifungal prophylaxis (posaconazole 51.0%, voriconazole 30.4%, itraconazole 17.7%). The median overall survival was 9.2\u2009months and relapse-free survival was 8.1\u2009months. Grades 3\u20134 neutropenia and febrile neutropenia occurred in 93.8% and 60.5% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This real-world practice highlights the feasibility and effectiveness of AZA-VEN in combination with antifungal prophylaxis for elderly or unfit AML patients in resource-limited countries. However, infectious complications remain a concern with this low-intensity regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251372770","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:22:26Z","timestamp":1757485346000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-4889","authenticated-orcid":false,"given":"Thanawat","family":"Rattanathammethee","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-2140","authenticated-orcid":false,"given":"Chantiya","family":"Chanswangphuwana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Rama IV Road, Patumwan, Bangkok 10330, Thailand"},{"name":"Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panachai","family":"Silpsamrit","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannadit","family":"Prayongratana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirichai","family":"Srichairatanakool","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerachat","family":"Punnachet","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonthakorn","family":"Hantrakun","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pokpong","family":"Piriyakhuntorn","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasinee","family":"Hantrakool","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatree","family":"Chai-Adisaksopha","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekarat","family":"Rattarittamrong","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Norasetthada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisak","family":"Tantiworawit","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.03.004"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.002"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0704-5"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000937"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3274"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac135"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.02.002"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2197090"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00784-y"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184618"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020584"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2343604"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.07.004"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242826"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25978"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2042688"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5459"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34608"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17003"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_3_4_29_2","unstructured":"Thai Society of Hematology Infectious Disease Association of Thailand. Guideline for treatment and prevention of febrile neutropenia in hematologic malignancies https:\/\/www.tsh.or.th\/file_upload\/files\/FN%20guidance%202024.pdf (2024 accessed 26 June 2025)."},{"key":"e_1_3_4_30_2","unstructured":"Infectious Disease Association of Thailand. Guidance for treatment of invasive fungal diseases 2025 https:\/\/idthai.org\/Contents\/Views\/?d=!17!9!!1059! (2025 accessed 26 June 2025)."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241311776"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2433172"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286089"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac486"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251372770","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251372770","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251372770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:55Z","timestamp":1777591075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251372770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"alternative-id":["10.1177\/20406207251372770"],"URL":"https:\/\/doi.org\/10.1177\/20406207251372770","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251372770"}}